Scancell Holdings stock analysis
Scancell Holdings (SCNLF) Stock Price & Analysis
SCNLF Stock Chart & Stats
- Day’s Range
- $1.02 - $1.06
- 52-Week Range
- $1.02 - $3.35
- Previous Close
- $1.04
- Volume
- N/A
- Average Volume (3M)
- 169
- Market Cap
- $126.89M
- Enterprise Value
- $209.19M
- Total Cash (Recent Filing)
- $5.32M
- Total Debt (Recent Filing)
- $17.08M
- Price to Earnings (P/E)
- ―
- Beta
- 0.50
- Next Earnings
- Feb 04, 2027 (Est.)
- EPS Estimate
- -0.12
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
FDA-cleared Phase III Pathway
FDA clearance validates the planned Phase III design, manufacturing package, endpoints, and statistical approach, materially reducing regulatory execution uncertainty. The surrogate endpoint could support an accelerated approval route, creating a clearer development and commercialization pathway if efficacy is confirmed.
Encouraging Clinical Signal
The Phase II signal provides meaningful evidence that iSCIB1+ may improve outcomes when added to established therapy, supporting further investment in the program. A biomarker identified for Phase III may also enrich responders and improve the efficiency of confirmatory development.
Platform And Partnered Pipeline
Scancell is developing multiple immunotherapy approaches rather than relying on a single candidate, while partnered antibodies provide additional potential milestones and royalties. Long patent protection, scalable manufacturing, and needle-free delivery support future commercial durability if clinical programs succeed.
Bears Say
Negative Equity And Asset Deterioration
Negative equity and a sharply reduced asset base indicate limited balance-sheet resilience relative to the company’s development obligations. With debt still about £17.1m, Scancell has less financial flexibility to absorb setbacks or fund strategic programs without additional external capital.
Persistent Cash Burn And Funding Need
Recurring operating and free-cash-flow outflows show that the business currently consumes capital rather than funding development internally. Continued burn increases dependence on financing, partnering, or milestone receipts, creating execution risk around sustaining operations and advancing the pipeline.
Long Path To Definitive Data
A blinded Phase III timeline extending to H2 2029 delays definitive confirmation of clinical benefit and potential product revenue. The extended development period requires Scancell to maintain funding for several years while efficacy updates remain limited, increasing financing and execution exposure.
SCNLF FAQ
What was Scancell Holdings’s price range in the past 12 months?
What is Scancell Holdings’s market cap?
When is Scancell Holdings’s upcoming earnings report date?
Is Scancell Holdings overvalued?
Does Scancell Holdings pay dividends?
What is Scancell Holdings’s EPS estimate?
How many shares outstanding does Scancell Holdings have?
Which hedge fund is a major shareholder of Scancell Holdings?
What is the TipRanks Smart Score and how is it calculated?
Scancell Holdings Stock Smart Score
Company Description
Scancell Holdings
Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The company's pipeline features several promising candidates, including SCIB1, currently in Phase II clinical trials for metastatic melanoma; SCIB2, aimed at non-small cell lung cancer; and Modi-1, which is undergoing Phase I/II studies for various indications such as head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is advancing Modi-2, a therapeutic agent specifically designed to target homocitrullinated cancer antigens. Its development efforts also encompass SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine engineered to provide protection against the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Phillip John L'Huillier
- Employees
- 60
- Website
- www.scancell.co.uk
- Address
- Unit 202 Bellhouse Building, Oxford, OX, OX4 4GD, GB
SCNLF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |









